Navigation Links
CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
Date:3/29/2009

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Results from a new sub- analysis of the JUPITER study show that patients with low to normal cholesterol levels and elevated high sensitivity C-reactive protein (hsCRP) who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/L with CRESTOR(R) (rosuvastatin calcium) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%; p=0.033). These new data were presented at the 58th Annual American College of Cardiology Scientific Sessions (ACC) in Orlando, Florida, and published simultaneously in The Lancet.

This analysis was conducted in approximately 15,500 patients, or 87% of the entire JUPITER cohort, representing patients who had LDL-C and hsCRP values assessed at baseline and one year.

Additional results from this analysis showed:

-- Patients who achieved an LDL-C <70 mg/dL experienced a 55% reduction in cardiovascular events compared to placebo

-- Patients who achieved a dual treatment target of LDL-C<70 mg/dL and hsCRP <1 mg/L achieved a 79% reduction in CV events compared to placebo

"JUPITER demonstrated the effect of rosuvastatin on cardiovascular morbidity and mortality," said Alex Gold, MD, Executive Director, Clinical Development, AstraZeneca US. "In this analysis, patients treated with rosuvastatin who achieved low levels of LDL-C and hsCRP had a greater reduction in cardiovascular events."

Rosuvastatin 20mg was well tolerated in nearly 9,000 patients during the course of the JUPITER study.

ABOUT JUPITER:

Results from the primary analysis of JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin), originally presented in November 2008 at the American Heart Association's Annual Scientific Sessions, and published by the
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
7. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
8. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
9. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
10. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
11. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)...  Luoxis Diagnostics, Inc., a subsidiary of Ampio ... its academic collaborators will present several peer-reviewed posters ... novel RedoxSYS Diagnostic System, a first-in-class platform that ... response to injury or illness.  A poster demonstrating ... marker will be presented by Christopher V. ...
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... development of therapeutic antibodies, today announced the appointment ... Development Officer. Dr. Londei will lead the preclinical ... "We are pleased to welcome ... Hamza Suria , President and Chief Executive ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
(Date:10/22/2014)... 22, 2014 During the Western United ... supply runs dangerously low, Southern Oregon’s water is proving ... despite the lowest mountain snow pack on record in ... and early autumn.* That was the observation of journalist-hikers ... book “Hiking Southern Oregon,” during an interview with water ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Although there are only ... time for many people who have trouble finding time within their ... to exercise for long periods of time to get in shape. ... goals while on the go. , Change Up Your Commute ... to work to add some exercise into your daily routine. If ...
(Date:10/22/2014)... Reinberg HealthDay Reporter , TUESDAY, ... weight and length may be showing a genetic propensity for ... certain genes have been linked to increased body fat, but ... and lean muscle, the researchers said. At 1 year, ... ages 2 and 3, however, these genes were linked to ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, ... vitro fertilization (IVF) -- the incubation of embryos in a ... inside the vagina, new research suggests. Scientists from the ... INVOcell, might sharply cut costs for pricey IVF procedures among ... to those who don,t live near big-city assisted reproduction centers, ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market ... of facts, figures and forecasts on the global medical ... forecast categories the Worldwide Medical Market Forecasts to ... views on the worldwide medical market to reveal key ... you data for 2010-2019, covering each country market individually, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... Arbor, Mich. Researchers have identified a gene mutation that causes ... according to U-M Medical School scientists. In the study ... Academy of Sciences USA, U-M,s Marci Lesperance, M.D., and ... examined the DNA of individuals from the same large family ...
... LA JOLLA, Calif., July 12, 2010 Some types ... to metastasize than others. Nearly one-third of these aggressive ... known as neuroendocrine-type cells. More rarely, some aggressive prostate ... The presence of neuroendocrine-type cancer cells is associated with ...
... Irvine, Calif., July 12, 2010 UC Irvine public ... research in impoverished reaches of China, Myanmar and Thailand, ... million of a seven-year, $14.5 million award to Pennsylvania ... Infectious Diseases. Yan will collaborate with Penn State principal ...
... A new Mayo Clinic study found that apathy and ... impairment (MCI), a disorder of the brain that affects ... Alzheimer,s disease and Lewy body dementia. The study was ... Honolulu on July 11, 2010. "An important ...
... to be much more complex than previously thought. In ... , Loyola University Health System researchers describe an example of ... be rare in bacteria. This discovery that protein acetylation ... a new age" in bacterial research, senior author Alan Wolfe, ...
... AIDS Society (IAS), conveners of the International AIDS Conference, ... Living with HIV (GNP+), the International Council of AIDS ... HIV/AIDS (ICW) and the United Nations Joint Programme on ... society and local partners for the XIX International AIDS ...
Cached Medicine News:Health News:U-M researchers identify gene mutation that causes rare form of deafness 2Health News:How prostate cancer packs a punch 2Health News:Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment 2Health News:'Dawning of a new age' in bacteria research 2Health News:Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced 2Health News:Civil society and local partners for XIX International AIDS Conference (AIDS 2012) announced 3
Esophageal and Anorectal Solid State Catheter Adapter Cable for Polygraf ID...
... of influenza A and B ... to the availability of effective ... influenza using Clearview Exact Influenza ... to reduced hospital stays, antimicrobial ...
... (532 nm) is the newest,addition to ... family is widely,accepted for its reliability, ... it makes,up the worlds largest installed ... OR laser was specifically,designed for the ...
...
Medicine Products: